5 Things to Know about Delta-8 Tetrahydrocannabinol – Delta-8 THC

Image

Delta-8 tetrahydrocannabinol, also known as delta-8 THC, is a psychoactive substance found in the Cannabis sativa plant, of which marijuana & hemp are two varieties. Delta-8 THC is one of over 100 cannabinoids produced naturally by the cannabis plant but is not found in significant amounts in the cannabis plant. As a result, concentrated amounts of delta-8 THC are typically manufactured from hemp-derived cannabidiol (CBD). 

It is important for consumers to be aware that delta-8 THC products have not been evaluated or approved by the FDA for safe use in any context. They may be marketed in ways that put the public health at risk & should especially be kept out of reach of children & pets. 

Here are 5 things you should know about delta-8 THC to keep you & those you care for safe from products that may pose serious health risks: 

1. Delta-8 THC products have not been evaluated or approved by the FDA for safe use & may be marketed in ways that put the public health at risk.

The FDA is aware of the growing concerns surrounding delta-8 THC products currently being sold online & in stores. These products have not been evaluated or approved by the FDA for safe use in any context. Some concerns include variability in product formulations & product labeling, other cannabinoid & terpene content, & variable delta-8 THC concentrations. Additionally, some of these products may be labeled simply as “hemp products,” which may mislead consumers who associate “hemp” with “non-psychoactive.” Furthermore, the FDA is concerned by the proliferation of products that contain delta-8 THC & are marketed for therapeutic or medical uses, although they have not been approved by the FDA. Selling unapproved products with unsubstantiated therapeutic claims is not only a violation of federal law, but also can put consumers at risk, as these products have not been proven to be safe or effective. This deceptive marketing of unproven treatments raises significant public health concerns because patients & other consumers may use them instead of approved therapies to treat serious & even fatal diseases.

2. The FDA has received adverse event reports involving delta-8 THC-containing products. 

From December 2020 through July 2021, the FDA received adverse event reports from both consumers & law enforcement describing 22 patients who consumed delta-8 THC products; of these, 14 presented to a hospital or emergency room for treatment following the ingestion. Of the 22 patients, 19 experienced adverse events after ingesting delta-8 THC-containing food products (e.g., brownies, gummies). Adverse events included vomiting, hallucinations, trouble standing, & loss of consciousness. 

National poison control centers received 661 exposure cases of delta-8 THC products between January 2018 & July 31, 2021, 660 of which occurred between January 1, 2021, & July 31, 2021. Of the 661 exposure cases:

• 41% involved unintentional exposure to delta-8 THC & 77% of these unintentional exposures affected pediatric patients less than 18 years of age. 
• 39% involved pediatric patients less than 18 years of age
• 18% required hospitalizations, including children who required intensive care unit (ICU) admission following exposure to these products. 

3. Delta-8 THC has psychoactive & intoxicating effects.

Delta-8 THC has psychoactive & intoxicating effects, similar to delta-9 THC (i.e., the component responsible for the “high” people may experience from using cannabis). The FDA is aware of media reports of delta-8 THC products getting consumers “high.”  The FDA is also concerned that delta-8 THC products likely expose consumers to much higher levels of the substance than are naturally occurring in hemp cannabis raw extracts. Thus, historical use of cannabis cannot be relied upon in establishing a level of safety for these products in humans.   

4. Delta-8 THC products often involve use of potentially harmful chemicals to create the concentrations of delta-8 THC claimed in the marketplace. 

The natural amount of delta-8 THC in hemp is very low, & additional chemicals are needed to convert other cannabinoids in hemp, like CBD, into delta-8 THC (i.e., synthetic conversion). Concerns with this process include:

• Some manufacturers may use potentially unsafe household chemicals to make delta-8 THC through this chemical synthesis process. Additional chemicals may be used to change the color of the final product. The final delta-8 THC product may have potentially harmful by-products (contaminants) due to the chemicals used in the process, & there is uncertainty with respect to other potential contaminants that may be present or produced depending on the composition of the starting raw material. If consumed or inhaled, these chemicals, including some used to make (synthesize) delta-8 THC & the by-products created during synthesis, can be harmful.
• Manufacturing of delta-8 THC products may occur in uncontrolled or unsanitary settings, which may lead to the presence of unsafe contaminants or other potentially harmful substances. 

5. Delta-8 THC products should be kept out of the reach of children & pets.

Manufacturers are packaging & labeling these products in ways that may appeal to children (gummies, chocolates, cookies, candies, etc.). These products may be purchased online, as well as at a variety of retailers, including convenience stores & gas stations, where there may not be age limits on who can purchase these products. As discussed above, there have been numerous poison control center alerts involving pediatric patients who were exposed to delta-8 THC-containing products. Additionally, animal poison control centers have indicated a sharp overall increase in accidental exposure of pets to these products. Keep these products out of reach of children & pets. 

Why is the FDA notifying the public about delta-8 THC?

A combination of factors has led the FDA to provide consumers with this information. These factors include: 

• An uptick in adverse event reports to the FDA & the nation’s poison control centers.
• Marketing, including online marketing of products, that is appealing to children.
• Concerns regarding contamination due to methods of manufacturing that may in some cases be used to produce marketed delta-8 THC products.

The FDA is actively working with federal & state partners to further address the concerns related to these products & monitoring the market for product complaints, adverse events, & other emerging cannabis-derived products of potential concern. The FDA will warn consumers about public health & safety issues & take action, when necessary, when FDA-regulated products violate the law.

How to report complaints & cases of accidental exposure or adverse events:

If you think you are having a serious side effect that is an immediate danger to your health, call 9-1-1 or go to your local emergency room. Health care professionals & patients are encouraged to report complaints & cases of accidental exposure & adverse events to the FDA’s MedWatch Safety Information & Adverse Event Reporting Program:

• Call an FDA Consumer Complaint Coordinator if you wish to speak directly to a person about your problem.
• Complete an electronic Voluntary MedWatch form online or call 1-800-332-1088 to request a reporting form, then complete & return to the address on the form, or submit by fax to 1-800-FDA-0178.
• Complete a paper Voluntary MedWatch form & mail it to the FDA.
• To report adverse events in animals to the FDA’s Center for Veterinary Medicine, please download & submit Form FDA 1932a found at: www.fda.gov/ReportAnimalAE.

For more information about Delta-8 THC:  CDC HEALTH ALERT NETWORK (HAN)

The American Association of Poison Control Centers (AAPCC) maintains the National Poison Data System (NPDS), which houses de-identified case records of self-reported information collected from callers during exposure management & poison information calls managed by the country’s poison control centers (PCCs). NPDS data do not reflect the entire universe of exposures to a particular substance as additional exposures may go unreported to PCCs; accordingly, NPDS data should not be construed to represent the complete incidence of U.S. exposures to any substance(s). Exposures do not necessarily represent a poisoning or overdose & AAPCC is not able to completely verify the accuracy of every report.  Findings based on NPDS data do not necessarily reflect the opinions of AAPCC.